According to filings with the U.S. Securities and Exchange Commission, Elucida Oncology is raising $40,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Geno Germano played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Elucida Oncology

Elucida Oncology, Inc., is a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy with its first-in-class, ultra-small nanoparticle CDot drug conjugate (CDC) platform. CDCs are designed to penetrate deeper into tumors and deliver a significantly higher payload compared to antibody drug conjugates (ADCs). This combined with greater avidity for the target antigen, longer retention in tumors with minimal systemic exposure due to rapid renal clearance confers unique Target or Clear properties. In preclinical studies, this has resulted in enhanced efficacy irrespective of antigen expression levels with reduced off-target toxicity, thereby potentially addressing the limitations of ADCs and other novel drug carriers.

To learn more about Elucida Oncology, visit http://www.elucidaoncology.com/

Contact:
Geno Germano, Chief Executive Officer
646-701-5391
https://www.linkedin.com/in/geno-germano-725526131/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.